The p53 pathway is deregulated in almost all tumours making it a prime target for new cancer drug development. This Review discusses the new approaches to drug discovery that are currently being used to target the p53 pathway and the progress made with the drugs that have been developed so far.
- Christopher J. Brown
- Sonia Lain
- David P. Lane